Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. Co.'s pipeline is comprised of four programs being developed initially for the treatment of I&I indications. Co.'s two primary programs, APG777 and APG808, which Co. is initially developing for the treatment of AD and COPD, respectively. Moreover, Co. is evaluating APG777 in additional I&I indications, including asthma, areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and prurigo nodularis. The APGE stock yearly return is shown above.
The yearly return on the APGE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APGE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|